Nature MedicineNEWS
Nature MedicineNEWS
Next-generation KRAS G12C inhibitor improves survival in lung cancer
Nature Medicine, Published online: 10 November 2026; doi:10.1038/d41591-026-00057-9 Phase 3 trial data show that the next-generation KRAS G12C inhibitor divarasib leads to longer progression-free…
Read at original source ↗
Comments
No comments yet. Be the first to contribute.
✎ Write a comment